An Overview of Ovarian Cancer : Molecular Processes Involved and Development of Target-based Chemotherapeutics
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Ovarian cancer is one of the leading gynecologic diseases with a high mortality rate worldwide. Current statistical studies on cancer reveal that over the past two decades, the fifth most common cause of death related to cancer in females of the western world is ovarian cancer. In spite of significant strides made in genomics, proteomics and radiomics, there has been little progress in transitioning these research advances into effective clinical administration of ovarian cancer. Consequently, researchers have diverted their attention to finding various molecular processes involved in the development of this cancer and how these processes can be exploited to develop potential chemotherapeutics to treat this cancer. The present review gives an overview of these studies which may update the researchers on where we stand and where to go further. The unfortunate situation with ovarian cancer that still exists is that most patients with it do not show any symptoms until the disease has moved to an advanced stage. Undoubtedly, several targets-based drugs have been developed to treat it, but drug-resistance and the recurrence of this disease are still a problem. For the development of potential chemotherapeutics for ovarian cancer, however, some theoretical approaches have also been applied. A description of such methods and their success in this direction is also covered in this review.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
---|---|
Enthalten in: |
Current topics in medicinal chemistry - 21(2021), 4 vom: 11., Seite 329-346 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Shaik, Basheerulla [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies |
---|
Anmerkungen: |
Date Completed 12.07.2021 Date Revised 12.07.2021 published: Print Citation Status MEDLINE |
---|
doi: |
10.2174/1568026620999201111155426 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM317507060 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM317507060 | ||
003 | DE-627 | ||
005 | 20231225163418.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2174/1568026620999201111155426 |2 doi | |
028 | 5 | 2 | |a pubmed24n1058.xml |
035 | |a (DE-627)NLM317507060 | ||
035 | |a (NLM)33183204 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Shaik, Basheerulla |e verfasserin |4 aut | |
245 | 1 | 3 | |a An Overview of Ovarian Cancer |b Molecular Processes Involved and Development of Target-based Chemotherapeutics |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 12.07.2021 | ||
500 | |a Date Revised 12.07.2021 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
520 | |a Ovarian cancer is one of the leading gynecologic diseases with a high mortality rate worldwide. Current statistical studies on cancer reveal that over the past two decades, the fifth most common cause of death related to cancer in females of the western world is ovarian cancer. In spite of significant strides made in genomics, proteomics and radiomics, there has been little progress in transitioning these research advances into effective clinical administration of ovarian cancer. Consequently, researchers have diverted their attention to finding various molecular processes involved in the development of this cancer and how these processes can be exploited to develop potential chemotherapeutics to treat this cancer. The present review gives an overview of these studies which may update the researchers on where we stand and where to go further. The unfortunate situation with ovarian cancer that still exists is that most patients with it do not show any symptoms until the disease has moved to an advanced stage. Undoubtedly, several targets-based drugs have been developed to treat it, but drug-resistance and the recurrence of this disease are still a problem. For the development of potential chemotherapeutics for ovarian cancer, however, some theoretical approaches have also been applied. A description of such methods and their success in this direction is also covered in this review | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Antibodies | |
650 | 4 | |a Computer-assisted artificial intelligenceTechniques | |
650 | 4 | |a Molecular hydrogen | |
650 | 4 | |a Ovarian cancer | |
650 | 4 | |a Quantum chemical drug discovery | |
650 | 4 | |a Targeted therapy | |
650 | 4 | |a Vitamin D | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
700 | 1 | |a Zafar, Tabassum |e verfasserin |4 aut | |
700 | 1 | |a Balasubramanian, Krishnan |e verfasserin |4 aut | |
700 | 1 | |a Gupta, Satya P |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current topics in medicinal chemistry |d 2001 |g 21(2021), 4 vom: 11., Seite 329-346 |w (DE-627)NLM117790141 |x 1873-4294 |7 nnns |
773 | 1 | 8 | |g volume:21 |g year:2021 |g number:4 |g day:11 |g pages:329-346 |
856 | 4 | 0 | |u http://dx.doi.org/10.2174/1568026620999201111155426 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 21 |j 2021 |e 4 |b 11 |h 329-346 |